Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP569630.RALyaQxZhMw9mMQL1zTT9Atqp1Enh7uPZvnB7yMYuHitQ130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP569630.RALyaQxZhMw9mMQL1zTT9Atqp1Enh7uPZvnB7yMYuHitQ130_assertion type Assertion NP569630.RALyaQxZhMw9mMQL1zTT9Atqp1Enh7uPZvnB7yMYuHitQ130_head.
- NP569630.RALyaQxZhMw9mMQL1zTT9Atqp1Enh7uPZvnB7yMYuHitQ130_assertion description "[MSH2 was reduced in 23.4% of NSCLC patients and was significantly associated with adenocarcinoma (P=0.024).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP569630.RALyaQxZhMw9mMQL1zTT9Atqp1Enh7uPZvnB7yMYuHitQ130_provenance.
- NP569630.RALyaQxZhMw9mMQL1zTT9Atqp1Enh7uPZvnB7yMYuHitQ130_assertion evidence source_evidence_literature NP569630.RALyaQxZhMw9mMQL1zTT9Atqp1Enh7uPZvnB7yMYuHitQ130_provenance.
- NP569630.RALyaQxZhMw9mMQL1zTT9Atqp1Enh7uPZvnB7yMYuHitQ130_assertion SIO_000772 24185125 NP569630.RALyaQxZhMw9mMQL1zTT9Atqp1Enh7uPZvnB7yMYuHitQ130_provenance.
- NP569630.RALyaQxZhMw9mMQL1zTT9Atqp1Enh7uPZvnB7yMYuHitQ130_assertion wasDerivedFrom befree-20150227 NP569630.RALyaQxZhMw9mMQL1zTT9Atqp1Enh7uPZvnB7yMYuHitQ130_provenance.
- NP569630.RALyaQxZhMw9mMQL1zTT9Atqp1Enh7uPZvnB7yMYuHitQ130_assertion wasGeneratedBy ECO_0000203 NP569630.RALyaQxZhMw9mMQL1zTT9Atqp1Enh7uPZvnB7yMYuHitQ130_provenance.